Illumina Reports Financial Results for Third Quarter of Fiscal Year 2026
Article excerpt
Highlighted: the sentence this signal was extracted from
SAN DIEGO , Oct. 29, 2026 /PRNewswire/ -- Illumina, Inc. (Nasdaq: ILMN ) ("Illumina" or the "company") today announced its financial results for the third quarter of fiscal year 2026. Third quarter 2026 results "In the third quarter, healthy clinical demand and robust NovaSeq X placements drove results above our guidance. Based on continued momentum, we are raising our full year revenue and earnings guidance," said Jacob Thaysen, Chief Executive Officer of Illumina. "As we continue to execute our strategy, our innovation is broadening the value of the Illumina ecosystem. Together with our customers, we are laying the foundation for AI to transform our understanding of human biology and improve patient outcomes." Fiscal year 2026 guidance For fiscal year 2026 and excluding tariff refunds, Illumina now expects: Third quarter results GAAP Non-GAAP (a) Non-GAAP Excluding Tariff Refunds (b) Dollars in millions, except per share amounts Q3 2026 Q3 2025 Q3 2026 Q3 2025 Q3 2026 Revenue $ 1,129 $ 1,084 $ 1,129 $ 1,084 $ 1,166 Gross margin 73.5 % 67.6 % 75.3 % 69.2 % 69.4 % Operating profit $ 305 $ 227 $ 325 $ 265 $ 292 Operating margin 27.0 % 21.0 % 28.8 % 24.5 % 25.0 % Diluted EPS $ 1.43 $ 0.98 $ 1.62 $ 1.34 $ 1.44 (a) See tables in "Results of Operations - Non-GAAP" section below for GAAP and non-GAAP reconciliations. (b) Excludes the impacts of International Emergency Economic...
Keep reading with a free account
The rest of this article, and every signal for Illumina, is in your free account.